Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review
- Author:
Sang Pyo LEE
1
;
Yoo Seob SHIN
;
Sung-Yoon KANG
;
Tae-Bum KIM
;
Sang Min LEE
Author Information
- Publication Type:Review Article
- From:Immune Network 2022;22(1):e12-
- CountryRepublic of Korea
- Language:English
- Abstract: Allergen-specific immunotherapy (AIT) is presumed to modulate the natural course of allergic disease by inducing immune tolerance. However, conventional AITs, such as subcutaneous immunotherapy and sublingual immunotherapy, require long treatment durations and often provoke local or systemic hypersensitivity reactions. Therefore, only <5% of allergy patients receive AIT as second-line therapy. Novel administration routes, such as intralymphatic, intradermal and epicutaneous immunotherapies, and synthetic recombinant allergen preparations have been evaluated to overcome these limitations. We will review the updated views of diverse AIT methods, and discuss the limitations and opportunities of the AITs for the treatment of allergic diseases in humans.
